Recombinant human soluble thrombomodulin is active against hemophagocytic lymphohistiocytosis associated with acquired immunodeficiency syndrome

International Journal of Hematology

Volumn 98, Issue 5, 2013, Pages 615-619

  Chi, SungGi ^a   Ikezoe, Takayuki ^a   Takeuchi, Asako ^a   Takaoka, Masato ^a   Yokoyama, Akihito ^a  

^a KOCHI UNIVERSITY   (Japan)

Author keywords

Disseminated intravascular coagulation; Hemophagocytic lymphohistiocytosis; Human immunodeficiency virus; Thrombomodulin

Indexed keywords

ABACAVIR; ALANINE AMINOTRANSFERASE; ALPHA 2 ANTIPLASMIN; AMPHOTERICIN B; ASPARTATE AMINOTRANSFERASE; ATOVAQUONE; C REACTIVE PROTEIN; D DIMER; FERRITIN; FIBRIN DEGRADATION PRODUCT; FIBRINOGEN; GAMMA GLUTAMYLTRANSFERASE; GAMMA INTERFERON; HEMOGLOBIN; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; METRONIDAZOLE; RALTEGRAVIR; RECOMBINANT THROMBOMODULIN; THROMBIN ANTITHROMBIN COMPLEX;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMEBIASIS; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD CLOTTING DISORDER; CASE REPORT; CEREBELLUM DISEASE; DISEASE ASSOCIATION; DISEASE SEVERITY; DISORIENTATION; DISSEMINATED INTRAVASCULAR CLOTTING; DYSARTHRIA; DYSPHAGIA; FERRITIN BLOOD LEVEL; FEVER; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HEMOPHAGOCYTIC SYNDROME; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; IMMUNE DEFICIENCY; LEUKOCYTE; LIVER DYSFUNCTION; LYMPHOCYTE COUNT; MALE; NEUTROPENIA; NYSTAGMUS; OPPORTUNISTIC INFECTION; PANCYTOPENIA; PARTIAL THROMBOPLASTIN TIME; PROTHROMBIN TIME; SORE THROAT; THROMBOCYTE;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DISSEMINATED INTRAVASCULAR COAGULATION; HUMANS; LYMPHOHISTIOCYTOSIS, HEMOPHAGOCYTIC; MALE; RECOMBINANT PROTEINS; THROMBOMODULIN; TREATMENT OUTCOME;

EID: 84892914625     PISSN: 09255710     EISSN: 18653774     Source Type: Journal    
DOI: 10.1007/s12185-013-1450-5     Document Type: Article

References (37)

1. Henter JI, Horne A, Arico M, Egeler RM, Filipovich AH, Imashuku S, Ladisch S, McClain K, Webb D, Winiarski J, Janka G. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007;48:124-31.
2. Feldmann J, Le Deist F, Ouachee-Chardin M, Certain S, Alexander S, Quartier P, Haddad E, Wulffraat N, Casanova JL, Blanche S, Fischer A, de Saint Basile G. Functional consequences of perforin gene mutations in 22 patients with familial haemophagocytic lymphohistiocytosis. Br J Haematol. 2002;117: 965.
3. Navarro WH, Kaplan LD. AIDS-related lymphoproliferative disease. Blood. 2006;107:13-20.
4. Baraldes MA, Domingo P, Gonzalez MJ, Aventin A, Coll P. Tuberculosis-associated hemophagocytic syndrome in patients with acquired immunodeficiency syndrome. Arch Intern Med. 1998;158:194-5.
5. Castilletti C, Preziosi R, Bernardini G, Caterini A, Gomes V, Calcaterra S, Carletti F, Capobianchi MR, Armignacco O. Hemophagocytic syndrome in a patient with acute human immunodeficiency virus infection. Clin Infect Dis. 2004;38:1792-3.
6. Gotoh M, Matsuda J, Gohchi K, Sanaka T, Kawasugi K. Successful recovery from human immunodeficiency virus (HIV)- associated haemophagocytic syndrome treated with highly active antiretroviral therapy in a patient with HIV infection. Br J Haematol. 2001;112:1090.
7. Lortholary A, Raffi F, Aubertin P, Barrier JH, Boibieux A, Peyramond D. HIV-associated haemophagocytic syndrome. Lancet. 1990;336:1128.
8. Park KH, Yu HS, Jung SI, Shin DH, Shin JH. Acute human immunodeficiency virus syndrome presenting with hemophagocytic lymphohistiocytosis. Yonsei Med J. 2008;49:325-8.
9. Sasadeusz J, Buchaman M, Speed B. Reactive heamophagocytic syndrome in human immunodeficiency virus infection. J Infect. 1990;20:65-8.
10. Sproat LO, Pantanowitz L, Lu CM, Dezube BJ. Human immunodeficiency virus-associated hemophagocytosis with iron-deficiency anemia and massive splenomegaly. Clin Infect Dis. 2003;37:170-3.
11. Huang DB, Wu JJ, Hamill RJ. Reactive hemophagocytosis associated with the initiation of highly active antiretroviral therapy (HAART) in a patient with AIDS. Scand J Infect Dis. 2004;36:516-9.
12. Henter JI, Samuelsson-Horne A, Arico M, Egeler RM, Elinder G, Filipovich AH, Gadner H, Imashuku S, Komp D, Ladisch S, Webb D, Janka G. Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunochemotherapy and bone marrow transplantation. Blood. 2002;100:2367.
13. Abeyama K, Stern DM, Ito Y, Kawahara K, Yoshimoto Y, Tanaka M, Uchimura T, Ida N, Yamazaki Y, Yamada S, Yamamoto Y, Yamamoto H, Iino S, Taniguchi N, Maruyama I. The N-terminal domain of thrombomodulin sequesters high-mobility group-B1 protein, a novel anti-inflammatory mechanism. J Clin Invest. 2005;115:1267-74.
14. Conway EM, Van de Wouwer M, Pollefeyt S, Jurk K, Van Aken H, De Vriese A, Weitz JI, Weiler H, Hellings PW, Schaeffer P, Herbert JM, Collen D, Theilmeier G. The lectin-like domain of thrombomodulin confers protection from neutrophil-mediated tissue damage by suppressing adhesion molecule expression via nuclear factor kappa-B and mitogen-activated protein kinase pathways. J Exp Med. 2002;196:565-77.
15. Ikezoe T, Yang J, Nishioka C, Honda G, Furihata M, Yokoyama A. Thrombomodulin protects endothelial cells from a calcineurin inhibitor-induced cytotoxicity by upregulation of extracellular signal-regulated kinase/myeloid leukemia cell-1 signaling. Arterioscler Thromb Vasc Biol. 2012;32:2259-70.
16. Esmon CT, Owen WG. Identification of an endothelial cofactor for thrombin-catalyzed activation of protein C. Proc Natl Acad Sci USA. 1981;78:2249-52.
17. Esmon CT, Esomn NL, Harris KW. Complex formation between thrombin and thrombomodulin inhibits both thrombin-catalyzed fibrin formation and factor V activation. J Biol Chem. 1982; 257:7944-7.
18. Maruyama I, Salem HH, Majerus PW. Coagulation factor Va binds to human umbilical vein endothelial cells and accelerates protein C activation. J Clin Invest. 1984;74:224-30.
19. McClain K, Gehrz R, Grierson H, et al. Virus-associated histiocytic proliferations in children Frequent association with Epstein-Barr virus and congenital or acquired immunodeficiencies. Am J Pediatr Hematol Oncol. 1988;10:196.
20. Chen TL, Wong WW, Chiou TJ. Hemophagocytic syndrome: An unusual manifestation of acute human immunodeficiency virus infection. Int J Hematol. 2003;78:450.
21. Chuang HC, Lay JD, Hsieh WC, et al. Epstein-Barr virus LMP1 inhibits the expression of SAP gene and upregulates Th1 cytokines in the pathogenesis of hemophagocytic syndrome. Blood. 2005;106:3090.
22. Arico M, Danesino C, Pende D, Moretta L. Pathogenesis of haemophagocytic lymphohistiocytosis. Br J Haematol. 2001; 114:761.
23. Billiau AD, Roskams T, Van Damme-Lombaerts R, Matthys P, Wouters C. Macrophage activation syndrome: characteristic findings on liver biopsy illustrating the key role of activated, IFN gamma- producing lymphocytes and IL-6- and TNF-alpha-producing macrophages. Blood. 2005;105(4):1648-51 Epub 2004 Oct 5.
24. van De venter SJ, Buller HR, ten Cate JW, Aarden LA, Hack CE, Sturk A. Experimental endotoxemia in humans: Analysis of cytokine release and coagulation, fibrinolytic, and complement pathways. Blood. 1990;76(12):2520-6.
25. Boermeester MA, van Leeuwen PA, Coyle SM, Wolbink GJ, Hack CE, Lowry SF. Interleukin-1 blockade attenuates mediator release and dysregulation of the hemostatic mechanism during human sepsis. Arch Surg. 1995;130(7):739-48.
26. Osterud B, Rao LV, Oslon JO. Induction of tissue factor expression in whole blood-lack of evidence for the presence of tissue factor expression on granulocytes. Thromb Haemost. 2000;83:861.
27. Cuccuini W, Poitevin S, Poitevin G, Dignat-George F, Cornillet- Lefebvre P, Sabatier F, Nguyen P. Tissue factor up-regulation in proinflammatory conditions confers thrombin generation capacity to endothelial colony-forming cells without influencing noncoagulant properties in vitro. J Thromb Haemost. 2010;8(9): 2042-52.
28. Sato K, Misawa N, Nie C, Satou Y, Iwakiri D, Matsuoka M, Takahashi R, Kuzushima K, Ito M, Takada K, Koyanagi Y. A novel animal model of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in humanized mice. Blood. 2011;117(21):5663-73.
29. Ikezoe T, Ikenoue N, Uchikawa N, Kojima S, Fukaya T, Yokoyama A. Use of recombinant human soluble thrombomodulin in the management of HELLP syndrome complicated by DIC. Thromb Res. 2010;126:238-40.
30. Yamakawa K, Ogura H, Fujimi S, Morikawa M, Ogawa Y, Mohri T, Nakamori Y, Inoue Y, Kuwagata Y, Tanaka H, Hamasaki T, Shimazu T. Recombinant human soluble thrombomodulin in sepsis-induced disseminated intravascular coagulation: A multicenter propensity score analysis. Intensive Care Med. 2013.
31. Ogawa Y, Yamakawa K, Ogura H, Kiguchi T, Mohri T, Nakamori Y, Kuwagata Y, Shimazu T, Hamasaki T, Fujimi S. Recombinant human soluble thrombomodulin improves mortality and respiratory dysfunction in patients with severe sepsis. J Trauma Acute Care Surg. 2012;72:1150-7.
32. Okamoto T, Tanigami H, Suzuki K, Shimaoka M. Thrombomodulin: A bifunctional modulator of inflammation and coagulation in sepsis. Crit Care Res Pract 2012;2012:614545.
33. Carnemolla R, Patel KR, Zaitsev S, Cines DB, Esmon CT, Muzykantov VR. Quantitative analysis of thrombomodulinmediated conversion of protein C to APC: Translation from in vitro to in vivo. J Immunol Methods. 2012;384(1-2):21-4. doi:10.1016/j.jim.2012.06.012 Epub 2012 Jun 27.
34. Bouwens EA, Stavenuiter F, Mosnier LO. Mechanisms of anticoagulant and cytoprotective actions of the protein C pathway. J Thromb Haemost. 2013;11(Suppl 1):242-53. doi:10.1111/jth. 12247.
35. Mosnier LO, Zlokovic BV, Griffin JH. The cytoprotective protein C pathway. Blood. 2007;109:3161-72.
36. Ranieri VM, Thompson BT, Barie PS, Dhainaut JF, Douglas IS, Finfer S, Gardlund B, Marshall JC, Rhodes A, Artigas A, Payen D, Tenhunen J, Al-Khalidi HR, Thompson V, Janes J, Macias WL, Van Gerow B, Williams MD, PROWESS-SHOCK Study Group. Drotrecogin alfa (activated) in adults with septic shock. N Engl J Med. 2012;366(22):2055-64.
37. Levi M, van der Poll T, ten Cate H, van De Venter SJ. The cytokine-mediated imbalance between coagulant and anticoagulant mechanisms in sepsis and endotoxaemia. Eur J Clin Invest. 1997;27:3.